News|Videos|November 16, 2023
Common Adverse Events With Second- and Third-Line Therapies in Patients With HER2+ mBC
Author(s)Joseph Gligorov, MD, PhD
Joseph Gligorov, MD, discusses the potential side effects of second- and third-line therapies for patients with HER2+ metastatic breast cancer and highlights the low-toxicity profile of tucatinib when combined with trastuzumab and capecitabine.
Advertisement
Episodes in this series
Advertisement
Related to this article
Camizestrant plus palbociclib did not significantly improve progression-free survival vs anastrozole plus palbociclib in the first-line SERENA-4 trial.
A UCLA-led review found there is not yet enough real-world evidence to determine whether using AI in routine screening actually reduces the number of breast cancers diagnosed between screenings
The FDA approved camizestrant for ESR1-mutated breast cancer, cleared ropeginterferon alfa-2b for essential thrombocythemia, and more.
The FDA approved camizestrant plus a CDK4/6 inhibitor for hormone receptor–positive, HER2-negative metastatic breast cancer that acquires an ESR1 mutation.
GLP-1 receptor agonists are generating buzz for their metabolic benefits, as well as for their potential to directly combat breast cancer progression.
Advertisement
Advertisement
Trending on OncLive
1
Adjuvant Osimertinib Keeps OS Benefit at 8 Years in Resected EGFR-Mutated Stage IB to IIIA NSCLC
2
PAPILLON: Frontline Amivantamab Plus Chemotherapy Yields 34.3-Month Median OS in EGFR Exon 20 Insertion–Positive NSCLC
3
Zidesamtinib Yields High Response Rates in TKI-Naive Advanced ROS1+ NSCLC
4
FDA Approves Aminolevulinic Acid Hydrochloride Plus PDT for Basal Cell Carcinoma
5